Neovacs S.A. (ALNEV.PA)

EUR 1.11

(-11.15%)

Total Debt Summary of Neovacs S.A.

  • Neovacs S.A.'s latest annual total debt in 2023 was 650 Thousand EUR , down -45.83% from previous year.
  • Neovacs S.A.'s latest quarterly total debt in 2024 Q2 was 480 Thousand EUR , down 0.0% from previous quarter.
  • Neovacs S.A. reported annual total debt of 1.2 Million EUR in 2022, up 16.69% from previous year.
  • Neovacs S.A. reported annual total debt of 1.02 Million EUR in 2021, up 164.8% from previous year.
  • Neovacs S.A. reported quarterly total debt of 650 Thousand EUR for 2023 Q4, down 0.0% from previous quarter.
  • Neovacs S.A. reported quarterly total debt of 650 Thousand EUR for 2023 FY, down -45.83% from previous quarter.

Annual Total Debt Chart of Neovacs S.A. (2023 - 2009)

Historical Annual Total Debt of Neovacs S.A. (2023 - 2009)

Year Total Debt Total Debt Growth
2023 650 Thousand EUR -45.83%
2022 1.2 Million EUR 16.69%
2021 1.02 Million EUR 164.8%
2020 388.36 Thousand EUR 558.24%
2019 59 Thousand EUR -74.46%
2018 231.04 Thousand EUR -90.58%
2017 2.45 Million EUR 203.39%
2016 808.65 Thousand EUR 8.99%
2015 741.93 Thousand EUR -80.44%
2014 3.79 Million EUR 0.15%
2013 3.78 Million EUR 12.12%
2012 3.37 Million EUR 272.69%
2011 906.36 Thousand EUR 26.22%
2010 718.06 Thousand EUR -81.86%
2009 3.95 Million EUR 0.0%

Peer Total Debt Comparison of Neovacs S.A.

Name Total Debt Total Debt Difference
ABIONYX Pharma SA 3.39 Million EUR 80.826%
ABIVAX Société Anonyme 55.46 Million EUR 98.828%
Adocia SA 13.08 Million EUR 95.034%
Aelis Farma SA 4.03 Million EUR 83.903%
Biophytis S.A. 8.27 Million EUR 92.14%
Advicenne S.A. 17.42 Million EUR 96.27%
genOway Société anonyme 7.23 Million EUR 91.014%
IntegraGen SA 1.12 Million EUR 42.209%
Medesis Pharma S.A. 1.2 Million EUR 45.833%
NFL Biosciences SA 62.17 Thousand EUR -945.453%
Plant Advanced Technologies SA 4.35 Million EUR 85.08%
Quantum Genomics Société Anonyme 2.71 Million EUR 76.075%
Sensorion SA 2.86 Million EUR 77.342%
Theranexus Société Anonyme 3.64 Million EUR 82.158%
TME Pharma N.V. 1.16 Million EUR 44.254%
Valbiotis SA 6.87 Million EUR 90.55%
TheraVet SA 1.15 Million EUR 43.959%
Valerio Therapeutics Société anonyme 8.99 Million EUR 92.776%
argenx SE 18.1 Million EUR 96.41%
BioSenic S.A. 28.16 Million EUR 97.692%
Celyad Oncology SA 902 Thousand EUR 27.938%
DBV Technologies S.A. 13.01 Million USD 95.007%
Galapagos NV 9.59 Million EUR 93.226%
Genfit S.A. 70.17 Million EUR 99.074%
GeNeuro SA 7.73 Million EUR 91.6%
Hyloris Pharmaceuticals SA 5.29 Million EUR 87.722%
Innate Pharma S.A. 39.89 Million EUR 98.371%
Inventiva S.A. 37.4 Million EUR 98.262%
MaaT Pharma SA 14.07 Million EUR 95.382%
MedinCell S.A. 58.96 Million EUR 98.898%
Nanobiotix S.A. 50.56 Million EUR 98.715%
Onward Medical N.V. 16.87 Million EUR 96.148%
Oryzon Genomics S.A. 13.68 Million EUR 95.251%
OSE Immunotherapeutics SA 45.8 Million EUR 98.581%
Oxurion NV 12.33 Million EUR 94.73%
Pharming Group N.V. 155.29 Million EUR 99.581%
Poxel S.A. 46.9 Million EUR 98.614%
GenSight Biologics S.A. 18.42 Million EUR 96.473%
Transgene SA 1.25 Million EUR 48.29%
Financière de Tubize SA 79.2 Million EUR 99.179%
UCB SA 3.03 Billion EUR 99.979%
Valneva SE 208.81 Million EUR 99.689%
Vivoryon Therapeutics N.V. 38 Thousand EUR -1610.526%